We are reducing our target price in Danaher as frustration is mounted after a messy quarter
Danaher's actions are under pressure on Wednesday, since the profit results of the fourth quarter of the Holding Club reached…
investment strategy
We are cutting a 2025 superior winner, obtaining profits in the movement of the market towards health actions
We are selling 75 shares of Ge Healthcare at approximately $ 90 each. After Monday's trade, Jim Cramer's charitable trust…
Our Five Best-Performing Stocks Since the December Monthly Meeting Are Tech-Free
It's been a topsy-turvy start to 2025 for the stock market. Since the Club's monthly meeting in December, Wall Street…
Strategas sees healthcare outperforming in 2025
The healthcare sector is poised to see a rebound and lead the market this year, according to analysts at Strategas,…
Stocks rise on cold inflation, hot bank profits and new rules on biotech exports to China
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
How much can you save if you don't drink for a month?
Ryanjlane | E+ | fake images The beginning of a new year is the most popular time to make a…
Eli Lilly's lead in the obesity race has increased. Its recent stock performance says otherwise.
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
Innovative biotech stocks have a good chance of breaking out in 2025
The trends may be turning in favor of biotech stocks in 2025 after several years of poor performance, but it…
Danaher had a disappointing 2024. Your path to success next year passes through Wall Street
Life sciences company Danaher certainly hasn't been an easy stock to buy this year. A wave of new companies going…
Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…